189 related articles for article (PubMed ID: 37251282)
1. The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study.
Liu Y; Zhang S; Hu R; Li C; Chen G; Shi X; Liu Y; Zheng K; Li H; Wen Y; Li X; Li X; Xia P; Qin Y
Int J Gen Med; 2023; 16():1983-1993. PubMed ID: 37251282
[TBL] [Abstract][Full Text] [Related]
2. Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.
Jiang Z; Cai M; Dong B; Yan Y; Wang Y; Li X; Shao C; Zuo L
BMC Nephrol; 2021 Apr; 22(1):148. PubMed ID: 33888083
[TBL] [Abstract][Full Text] [Related]
3. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of atypical membranous nephropathy with unknown etiology in adult Chinese patients.
Jiang Z; Cai M; Dong B; Yan Y; Yang B; Wang M; Wang Y; Li X; Lian L; Li S; Zuo L
Medicine (Baltimore); 2018 Aug; 97(32):e11608. PubMed ID: 30095619
[TBL] [Abstract][Full Text] [Related]
5. Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.
Zhu F; Chu X; Guo Y; Li Y; Cao C; Wu J; Xu H; Deng X; Li J; Liu X; Yao Y; Zeng R
Am J Transl Res; 2021; 13(7):7622-7631. PubMed ID: 34377239
[TBL] [Abstract][Full Text] [Related]
6. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
7. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience.
Wang YW; Wang XH; Wang HX; Yu RH
World J Clin Cases; 2023 Jan; 11(3):566-575. PubMed ID: 36793628
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
10. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis.
Huang L; Dong QR; Zhao YJ; Hu GC
Int Urol Nephrol; 2021 Jan; 53(1):111-119. PubMed ID: 32944889
[TBL] [Abstract][Full Text] [Related]
12. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
13. Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.
Bagchi S; Subbiah AK; Bhowmik D; Mahajan S; Yadav RK; Kalaivani M; Singh G; Dinda A; Kumar Agarwal S
Clin Kidney J; 2018 Jun; 11(3):337-341. PubMed ID: 29942496
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in patients with membranous nephropathy and kidney insufficiency.
Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
[No Abstract] [Full Text] [Related]
18. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
[TBL] [Abstract][Full Text] [Related]
19. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for the treatment of membranous nephropathy: a single-center experience.
Aleš Rigler A; Jerman A; Orsag A; Kojc N; Kovač D; Škoberne A; Borštnar Š; Večerić Haler Ž; Avguštin N; Kveder R; Ferluga D; Vizjak A; Lindič J
Clin Nephrol; 2017 Supplement 1; 88(13):27-31. PubMed ID: 28664837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
